China's economic weakness and its AI ambitions are putting competing demands on policymakers.

• Reviving the economy means getting households to spend more, but competing with the U.S. in AI means turbocharging an already production-heavy economic model.

Why it matters: China's push to supercharge production even as domestic demand weakens leaves China's producers more reliant on foreign buyers and pressures industries abroad.

The intrigue: Data overnight shows China's divide widening.

What they're saying: Arjen van Dijkhuizen, a senior economist at Dutch bank ABN Amro, wrote in a note this morning that the July data shows a widening gap between what China produces and consumes, potentially fueling further trade tensions with major partners.

• "Although Chinese exports are still benefiting from the global tech/AI boom, the re-escalation of tensions in the Middle East and the broadening of weakness in domestic demand mean that the balance of risks to the Chinese economy is shifting into a negative direction again," he wrote.

Driving the news: China's economy lost momentum in July, with consumer spending barely growing alongside a deepening investment slump.

• Retail sales rose just 0.6% compared with the same period a year ago, slowing further from June.
• Fixed-asset investment fell nearly 7% in the first seven months of 2026 as China's yearslong property bust continued to weigh heavily on activity. Real estate investment plunged 19%, while sales of newly built properties fell by double digits.
• The data suggests that the slowdown that took hold in the spring is continuing: GDP grew 4.3% from a year earlier in the second quarter, data released last month showed, down sharply from 5% in the first quarter.

The other side: China's factory engine continued to roar, even as demand at home remained weak.

• Industrial output rose 4.5% in July from a year earlier, while high-tech manufacturing rose nearly 14% in the first seven months of the year, extending a manufacturing boom that has been particularly strong in AI-related industries.

What to watch: Beijing recognizes the imbalance, with a top statistics official acknowledging that "strong supply and weak demand" remains a prominent problem.

• Policymakers have extended consumer support measures introduced in recent years, including subsidies under its car and appliance trade-in programs.
• But they have stopped short of the type of large-scale fiscal support that some economists believe is necessary to boost household demand.

Friction point: The AI race could deepen China's longstanding economic imbalance by making its industrial base more productive without necessarily boosting demand at home.

The bottom line: China's AI push raises the stakes in an already fraught debate over how much Chinese production the rest of the world can absorb. At a certain point, it becomes unsustainable.

• The pressures are already visible in Europe's battered auto industry that's teetering on the brink of crisis.

We've written plenty about the government policies as inflation accelerants, including tariffs.

• But another, quieter force is pulling prices in the opposite direction, with government policy at least somewhat to blame.

What's going on: Prescription drug prices fell 0.8% in July and are down 3.1% from a year ago — the steepest annual decline in more than six decades, according to the recent Consumer Price Index.

• It's a striking reversal for one of health care's most stubbornly expensive necessities, amid a major Washington push to lower drug costs.
• Prices haven't risen in any month this year, an unusually persistent stretch of flat or falling drug prices, even as costs for hospital and physician services continue to rise.

The intrigue: Trump administration officials are taking a victory lap for the price drop, although TrumpRx — the administration's website connecting patients with discounted cash prices for certain drugs — likely accounts for only part of the decline.

• Another potential factor: Medicare negotiations established under the Biden-era Inflation Reduction Act took effect in January for 10 of the program's costliest drugs, with negotiated prices as much as 79% below their list prices.

Zoom out: Changes in what Medicare pays pharmacies can show up in the prescription drug CPI.

• The government tracks the prices that pharmacies receive from patients and insurers, including Medicare, not just what consumers pay out of pocket.
• Manufacturer rebates paid after the transaction are not captured in the index, the Bureau of Labor Statistics told Axios.

What they're saying: Geoffrey Joyce, a USC health economist, said that TrumpRx makes discounts easier to find but often points consumers to prices that already exist.

• "If you were going to give policy credit, you'd have to say the IRA," Joyce said. Still, he added, much of the decline is being driven by market forces.
• As blockbuster drugs lose patent protection, cheaper generics enter the market, a shift the government's inflation gauge is designed to capture.

What we're watching: Falling prices in the aggregate do not necessarily translate into relief for all consumers, given the complexity of drug pricing and payments.

Caitlin Owens and Adriel Bettelheim contributed reporting.

Go deeper